• +1-646-491-9876
    • +91-20-67278686

    Search

    Erectile Dysfunction - Pipeline Review, H1 2017

    Erectile Dysfunction - Pipeline Review, H1 2017

    • Report Code ID: RW0001689458
    • Category Healthcare
    • No. of Pages 103
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

    Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 4, 2, 2, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

    Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
    - The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Erectile Dysfunction - Overview
    Erectile Dysfunction - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Erectile Dysfunction - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Erectile Dysfunction - Companies Involved in Therapeutics Development
    Apricus Biosciences Inc
    Astellas Pharma Inc
    Biolab Farmaceutica Ltda
    Biopharm GmbH
    Can-Fite BioPharma Ltd
    Fabre-Kramer Pharmaceuticals Inc
    Futura Medical Plc
    Hanmi Pharmaceuticals Co Ltd
    Humanetics Corp
    IntelGenx Corp
    Ion Channel Innovations LLC
    iX Biopharma Ltd
    Mezzion Pharma Co Ltd
    Mitsubishi Tanabe Pharma Corp
    Monosol Rx LLC
    NAL Pharmaceuticals Ltd
    Palatin Technologies Inc
    Pharmicell Co Ltd
    Suda Ltd
    XuanZhu Pharma Co Ltd
    Yungjin Pharm Co Ltd
    Erectile Dysfunction - Drug Profiles
    (tadalafil + tamsulosin hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alprostadil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AP-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    avanafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIO-300 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BL-214 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellgram-ED - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-602 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fadanafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FKK-01PD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HCP-1302 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPED-2015 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MED-2002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MED-2005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mirabegron ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pVAX-hSlo - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sildenafil citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sildenafil citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sildenafil citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SUD-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T-6932 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tadalafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tadalafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tadalafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TF-0092 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TPN-729 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TR-399 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    udenafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VLFIA-330 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YBH-1603 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Erectile Dysfunction - Dormant Projects
    Erectile Dysfunction - Discontinued Products
    Erectile Dysfunction - Product Development Milestones
    Featured News & Press Releases
    Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm
    Jan 24, 2017: Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy
    Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil
    Nov 28, 2016: MonoSol Rx Submits New Drug Application for Tadalafil PharmFilm
    Nov 09, 2016: Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
    Sep 13, 2016: iX Biopharma Announces Positive Results from Pivotal Study of Erectile Dysfunction Drug
    Jul 27, 2016: VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
    May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting
    Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
    Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil
    Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix
    Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
    Jan 27, 2015: Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
    Dec 09, 2014: Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
    Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Erectile Dysfunction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H1 2017
    Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2017
    Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H1 2017
    Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2017
    Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
    Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2017
    Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2017
    Erectile Dysfunction - Pipeline by IntelGenx Corp, H1 2017
    Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H1 2017
    Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Erectile Dysfunction - Pipeline by Monosol Rx LLC, H1 2017
    Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H1 2017
    Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Suda Ltd, H1 2017
    Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
    Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H1 2017
    Erectile Dysfunction - Dormant Projects, H1 2017
    Erectile Dysfunction - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Erectile Dysfunction - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Erectile Dysfunction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Apricus Biosciences Inc
    Astellas Pharma Inc
    Biolab Farmaceutica Ltda
    Biopharm GmbH
    Can-Fite BioPharma Ltd
    Fabre-Kramer Pharmaceuticals Inc
    Futura Medical Plc
    Hanmi Pharmaceuticals Co Ltd
    Humanetics Corp
    IntelGenx Corp
    Ion Channel Innovations LLC
    iX Biopharma Ltd
    Mezzion Pharma Co Ltd
    Mitsubishi Tanabe Pharma Corp
    Monosol Rx LLC
    NAL Pharmaceuticals Ltd
    Palatin Technologies Inc
    Pharmicell Co Ltd
    Suda Ltd
    XuanZhu Pharma Co Ltd
    Yungjin Pharm Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//erectile-dysfunction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//erectile-dysfunction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//erectile-dysfunction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments